Artivion | CRY - Selling And Administration Expenses


Artivion reported $55.75M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Abbott USD 3.13B 125M Dec/2025
Accuray USD 127.32M 500.16M Sep/2025
AngioDynamics USD 36.57M 3.79M Sep/2025
Artivion USD 55.75M 4.54M Dec/2025
AtriCure USD 78.34M 109K Dec/2025
Baxter International USD 761M 53M Dec/2025
Becton, Dickinson and Co. USD 1.39B 27M Dec/2025
Boston Scientific USD 1.83B 93M Dec/2025
Edwards Lifesciences USD 602.9M 88.3M Dec/2025
Inogen USD 43.77M 510K Jun/2024
Integra LifeSciences USD 156.45M 12.6M Dec/2025
J&J USD 6.75B 831M Dec/2025
Mesa Laboratories USD 27.31M 380K Sep/2024
Orthofix International USD 130.35M 11.31M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
ResMed USD 278.4M 19.2M Dec/2025
Stryker USD 2.14B 150M Dec/2025
Surmodics USD 11.4M 3.18M Jun/2025
Tandem Diabetes Care USD 99.86M 5.34M Dec/2025
Teleflex USD 222.37M 59.4M Dec/2025
Terumo JPY 105.26B 7.38B Dec/2025
Trinity Biotech USD 6.19M 2.18M Sep/2025